DDO-4033
DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM) . DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research[1].
Product Specifications
UNSPSC
12352005
Target
E1/E2/E3 Enzyme; YAP
Related Pathways
Metabolic Enzyme/Protease; Stem Cell/Wnt
Field of Research
Cancer
Smiles
C#CC1=C([N+]([O-])=O)C=C(C(NC2=CC(C)=NN2C(N3)=NC(CCC)=CC3=O)=O)C=C1
Molecular Formula
C20H18N6O4
Molecular Weight
406.39
References & Citations
[1]Zhang Q, et al. Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy. J Med Chem. 2025 Jul 24;68 (14) :14945-14961.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC042853-100 1x 100 µL
CD54 / ICAM-1 (15.2), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740031-500 1x 500 µL
Mucin 5AC (MUC5AC) (45M1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681003-500 1x 500 µL
Mucin 5AC (MUC5AC) (58M1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details